Targeting IL-10, ZO-1 gene expression and IL-6/STAT-3 trans-signalling by a combination of atorvastatin and mesalazine to enhance anti-inflammatory effects and attenuate progression of oxazolone-induced colitis

Fundam Clin Pharmacol. 2021 Feb;35(1):141-142. doi: 10.1111/fcp.12638. Epub 2020 Dec 21.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anti-Inflammatory Agents / therapeutic use
  • Atorvastatin / therapeutic use
  • Colitis* / drug therapy
  • Gene Expression
  • Humans
  • Interleukin-10 / genetics
  • Interleukin-6
  • Mesalamine / therapeutic use
  • Oxazolone* / therapeutic use

Substances

  • Anti-Inflammatory Agents
  • Interleukin-6
  • Interleukin-10
  • Oxazolone
  • Mesalamine
  • Atorvastatin